Joint Development and Commercial Agreement of KHK4083 with Amgen

Kyowa Kirin Co., Ltd.

Agenda

Joint Development and Commercial Agreement of KHK4083 with Amgen

Managing Executive Officer, Director of Corporate Strategy & Planning **Takeyoshi Yamashita, Ph.D.**

Q&A

Managing Executive Officer, Director of Corporate Strategy & Planning **Takeyoshi Yamashita, Ph.D.**

Executive Officer, Director of Global Product Strategy **Tomohiro Sudo**

Executive Officer, Vice President and Head of R&D **Yoshifumi Torii, Ph.D.**

Executive Officer, Director of Finance **Motohiko Kawaguchi**

Executive Officer, Director of Business Development **Yasuo Fujii**

This document contains certain forward-looking statements relating to such items as the company's (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasonable assumptions made by the company in making its forecasts, but the actual results in practice may differ substantially due to uncertain factors.

These uncertain factors include, but are not limited to, potential risks of the business activities in the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of side effects, regulatory risks, product defect risks, risks of changes to the prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.

This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.

Background and Update

- KHK4083 is an anti-OX40 fully human monoclonal antibody using Potelligent technology and fully human antibody production technology, both developed in-house by Kyowa Kirin.
- Phase 1b study of KHK4083 for moderate to severe atopic dermatitis demonstrated sustained efficacy even months after dosing completion, with an acceptable safety profile.
- In phase 2b study for moderate to severe atopic dermatitis, all the KHK4083 dosing regimen achieved the primary endpoint. (Detailed data to be presented at a medical congress during 21H2)
- To maximize the product value of KHK4083 for atopic dermatitis and its potential in other autoimmune disease treatments, today, **Kyowa Kirin and Amgen have entered into an agreement to develop and commercialize KHK4083 jointly**.

Development and Commercial Conditions

	US	Europe and Asia (ex. JP)	JP
Development	• Amgen leads development • Share development cost	• Amgen leads development • Share development cost	• Kyowa Kirin leads development
Commercialization	• Amgen commercializes and books sales • Kyowa Kirin co-promotes and shares cost	• Amgen commercializes and books sales • Kyowa Kirin has opt-in rights for co-promotion	• Kyowa Kirin commercializes and books sales
Sales Royalties	• Double-digit royalty to Kyowa Kirin	• Double-digit royalty to Kyowa Kirin	
Commercial supply	• Amgen supplies	• Amgen supplies	• Kyowa Kirin supplies

Amgen will make a $400 million up-front payment to Kyowa Kirin and future contingent milestone payments potentially worth up to an additional $850 million, as well as royalty payments on future global sales.

Atopic Dermatitis Market

Global AD market forecast



Estimated AD patient numbers

Moderate to severe AD (US+EU5+JP)

Prevalent cases: 30M

Diagnosed cases: 14M

Drug-treated

US 5.1M

EU5 3.6M

JP 0.7M

About KHK4083

Mechanism of action



EASI profile in phase 1b study



EASI at week 22 had decreased by 74.12% from baseline

Kyowa Kirin Co., Ltd.
Corporate Communications Dept., IR Group
+81-3-5205-7206 / ir@kyowakirin.com